NEW YORK (GenomeWeb) – Bioinformatics firm Berg said today that it is extending an ongoing collaboration with the University of Miami's Leonard M. Miller School of Medicine aimed at better understanding cardiovascular disease, identifying new biomarkers, and developing new treatments.
As part of the partnership, theUniversityofMiamiwill provide Berg access to clinical tissue samples obtained with patients' consent from its Miller School of Medicine. According to the collaborators, this is the first time theUniversityofMiamihas given a private research company access to these samples.
Berg will then use its Interrogative Biology platform to analyze the tissues in an effort to uncover novel biomarkers for the prevention of cardiac dysfunction and heart failure.
"This will enable stratification of patients based on disease onset and progression, and facilitate timely clinical intervention to improve patient outcomes," Rangaprasad Sarangarajan, chief scientific officer and co-founder of Berg Biosystems, said in a statement.